SPC for darunavir considered invalid in Dutch preliminary relief proceedings
Synapse
March 2019
by multiple authors
Recent developments in biosimilars settlements, market landscape and antitrust scrutiny
by multiple authors
Border issues: medical devices, wellbeing and lifestyle apps
The borderline between medical devices and wellbeing/lifestyle apps has become thinner with advances in technology and increased public demand for apps that track our physiological functions, remind us when to take medication or help to improve our health and wellbeing.
2 of 5 Insights
Protecting prosthetics patients and intellectual property
As with all areas of medical technology, where there is innovation, then regulation and intellectual property issues are not far behind. This is illustrated by the regulatory framework surrounding neural prosthetics.
5 of 5 Insights
Supplementary protection certificates: where are we and where are we going? (an update)
Synapse - February 2019
by multiple authors
Supplementary protection certificates: where are we and where are we going? (an update)
Plausibility of second medical use patents: pregabalin in the Supreme Court
The grant of an SPC for a new therapeutic application
Biosimilars – pricing and reimbursement and the competitive landscape
by multiple authors
Infringement of second medical use patents in the UK: pregabalin in the Supreme Court